Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.

Scientific reports - 3 Mar 2020

Friese Christina, Harbst Katja, Borch Troels Holz, Westergaard Marie Christine Wulff, Pedersen Magnus, Kverneland Anders, Jönsson Göran, Donia Marco, Svane Inge Marie, Met Özcan

Abstract excerpt

Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) can induce durable complete tumor regression in patients with advanced melanoma. Efforts are currently underway to expand this treatment modality to other cancer types. In the microenvironment of ovarian cancer, the engagement of co-inhibitory immune checkpoint molecules such as CTLA-4 can lead to the inactivation of TILs. Thus,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Count

Share to CTLA-4 Antigen

Share to Lymphocytes, Tumor-Infiltrating

Share to Ovarian Neoplasms

Share to Phenotype

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 32127601
DOI: 10.1038/s41598-020-60738-4
PMCID: PMC7054305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer.PMID 32127601Read ↗

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.Semantic proximity Read ↗

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignanciesSemantic proximity Read ↗

Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunitySemantic proximity Read ↗

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacySemantic proximity Read ↗

THE IMMUNOTHERAPY OF SOLID CANCERS BASED ON CLONING THE GENES ENCODING TUMOR-REJECTION ANTIGENSSemantic proximity Read ↗

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.Semantic proximity Read ↗

Short term inhibition of immune checkpoint proteins increases ex vivo expansion of tumour infiltrating lymphocytes in high grade serous ovarian cancerSemantic proximity Read ↗

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist TherapySemantic proximity Read ↗

PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for CancerSemantic proximity Read ↗

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.Semantic proximity Read ↗

Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma.Semantic proximity Read ↗

Mesothelin-Specific CAR T Cells Target Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.